BSE: 0 | NSE: ZENITHDRUG | Pharmaceuticals & Drugs | Small Cap
Past 10 year's financial track record analysis by Moneyworks4me indicates that Zenith Drugs Ltd is a average quality company.
The key valuation ratios of Zenith Drugs Ltd's currently when compared to its past seem to suggest it is in the Undervalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Zenith Drugs Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
| Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|
| ROCE % ⓘ | 24.3% | 23.9% | 25.1% | 25.2% | - |
| Value Creation Index ⓘ | 0.7 | 0.7 | 0.8 | 0.8 | - |
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ | |||||
| Sales ⓘ | 73.4 | 91.7 | 115 | 132 | 132 |
| Sales YoY Gr. | - | 24.9% | 24.9% | 14.9% | - |
| Adj EPS ⓘ | 2.6 | 2.7 | 4.5 | 6.2 | 5.6 |
| YoY Gr. | - | 4.7% | 69% | 35.8% | - |
| BVPS (₹) ⓘ | 8 | 10.7 | 14.8 | 36.3 | 36.3 |
| Adj Net Profit ⓘ | 3.1 | 3.2 | 5.4 | 10.6 | 10 |
| Cash Flow from Ops. ⓘ | -0.9 | 4.9 | -4.3 | -12.5 | - |
| Debt/CF from Ops. ⓘ | -17.5 | 3.4 | -6 | -1.9 | - |
CAGR Colour Code Guide ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | NA | NA | 21.5% | 14.9% | ||||
| Adj EPS ⓘ | NA | NA | 33.9% | 35.8% | ||||
| BVPSⓘ | NA | NA | 65.3% | 145.5% | ||||
| Share Price | - | - | - | - | ||||
Performance Ratio Colour Code Guide ⓘ
| Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|
| Return on Equity % ⓘ | 31.8 | 28.6 | 35.5 | 26.4 | 15.3 |
| Op. Profit Mgn % ⓘ | 9.8 | 7.6 | 8.8 | 12.5 | NAN |
| Net Profit Mgn % ⓘ | 4.2 | 3.5 | 4.8 | 8 | 7.2 |
| Debt to Equity ⓘ | 1.6 | 1.3 | 1.4 | 0.4 | - |
| Working Cap Days ⓘ | 0 | 159 | 198 | 239 | 0 |
| Cash Conv. Cycle ⓘ | 0 | 16 | 14 | 37 | 0 |
Sales growth is growing at healthy rate in last 3 years 21.49%
Net Profit is growing at healthy rate in last 3 years 33.93%
Debt to equity has declined versus last 3 years average to 0.38
Return on Equity has declined versus last 3 years average to 15.30%
Sales growth is not so good in last 4 quarters at 0.00%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 5.6 | 5.6 |
| TTM Sales (₹ Cr.) | 132 | 132 |
| BVPS (₹.) ⓘ | 36.3 | 36.3 |
| Reserves (₹ Cr.) ⓘ | 45 | 45 |
| P/BV ⓘ | 2.72 | 2.72 |
| PE ⓘ | 17.75 | 17.64 |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 0.00 / 0.00 |
| All Time Low / High (₹) | - / - |
| Market Cap (₹ Cr.) | 169 |
| Equity (₹ Cr.) | 17.2 |
| Face Value (₹) | 10 |
| Industry PE ⓘ | 43 |
| Pledged * | 0.00 | 0.00 |
| PARTICULARS | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|
| Sales | 73 | 92 | 115 | 132 |
| Operating Expenses ⓘ | 66 | 85 | 105 | 115 |
| Manufacturing Costs | 2 | 3 | 29 | 37 |
| Material Costs | 52 | 73 | 56 | 57 |
| Employee Cost | 2 | 3 | 4 | 5 |
| Other Costs ⓘ | 10 | 7 | 15 | 16 |
| Operating Profit ⓘ | 7 | 7 | 9 | 16 |
| Operating Profit Margin (%) | 9.8% | 7.6% | 8.0% | 12.5% |
| Other Income ⓘ | 0 | 1 | 1 | 3 |
| Interest ⓘ | 1 | 2 | 2 | 3 |
| Depreciation ⓘ | 1 | 1 | 1 | 1 |
| Exceptional Items ⓘ | 0 | 0 | 0 | -1 |
| Profit Before Tax ⓘ | 5 | 4 | 7 | 13 |
| Tax ⓘ | 2 | 1 | 2 | 4 |
| Profit After Tax | 3 | 3 | 5 | 10 |
| PAT Margin (%) | 4.2% | 3.5% | 4.3% | 7.2% |
| Adjusted EPS (₹) | 2.6 | 2.7 | 4.1 | 5.6 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 9% |
| PARTICULARS | Mar'21 | Mar'22 | Mar'23 | Mar'24 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | ||||||||||
| Shareholders Fund | 10 | 13 | 18 | 62 | ||||||
| Share Capital ⓘ | 0 | 0 | 0 | 17 | ||||||
| Reserves ⓘ | 9 | 12 | 17 | 45 | ||||||
| Minority Interest | 0 | 0 | 0 | 0 | ||||||
| Debt | 15 | 17 | 23 | 22 | ||||||
| Long Term Debt | 7 | 8 | 8 | 8 | ||||||
| Short Term Debt | 8 | 9 | 16 | 14 | ||||||
| Trade Payables | 20 | 34 | 51 | 43 | ||||||
| Others Liabilities ⓘ | 1 | 2 | 5 | 7 | ||||||
| Total Liabilities ⓘ | 47 | 66 | 97 | 134 | ||||||
Fixed Assets | ||||||||||
| Gross Block | 14 | 17 | 18 | 20 | ||||||
| Accumulated Depreciation | 5 | 6 | 8 | 9 | ||||||
| Net Fixed Assetsⓘ | 9 | 10 | 11 | 11 | ||||||
| CWIP ⓘ | 0 | 0 | 0 | 4 | ||||||
| Investmentsⓘ | 0 | 0 | 0 | 0 | ||||||
| Inventories | 7 | 12 | 24 | 26 | ||||||
| Trade Receivables | 23 | 32 | 49 | 67 | ||||||
Cash Equivalents  ⓘ
| 2 | 3 | 0 | 9 | ||||||
| Others Assetsⓘ | 5 | 9 | 13 | 17 | ||||||
| Total Assets ⓘ | 47 | 66 | 97 | 134 | ||||||
| PARTICULARS | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ | -1 | 5 | -4 | -12 |
| PBT ⓘ | 5 | 4 | 7 | 13 |
| Adjustment ⓘ | 3 | 3 | 4 | 4 |
| Changes in Working Capital ⓘ | -7 | -2 | -13 | -26 |
| Tax Paid ⓘ | -1 | -1 | -2 | -4 |
| Cash Flow From Investing Activity ⓘ | -1 | -3 | -2 | 26 |
| Capex | -1 | -3 | -2 | -5 |
| Net Investments | 0 | 0 | 0 | 35 |
| Others ⓘ | 0 | 0 | 0 | -4 |
| Cash Flow From Financing Activityⓘ | 3 | -1 | 6 | -4 |
| Net Proceeds from Shares ⓘ | 0 | 0 | 0 | 0 |
| Net Proceeds from Borrowing ⓘ | 0 | 0 | 0 | 0 |
| Interest Paid ⓘ | -1 | -2 | -2 | -3 |
| Dividend Paid ⓘ | 0 | 0 | 0 | 0 |
| Others ⓘ | 4 | 1 | 9 | -2 |
| Net Cash Flow ⓘ | 1 | 1 | 0 | 9 |
| PARTICULARS | Mar'21 | Mar'22 | Mar'23 | Mar'24 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 31.82 | 28.57 | 31.92 | 23.86 | ||||||
| ROCE (%) | 24.25 | 23.87 | 25.12 | 25.2 | ||||||
| Asset Turnover Ratio | 1.74 | 1.8 | 1.57 | 1.3 | ||||||
| PAT to CFO Conversion(x) | -0.33 | 1.67 | -0.8 | -1.2 | Working Capital Days | |||||
| Receivable Days | 105 | 100 | 116 | 142 | ||||||
| Inventory Days | 31 | 34 | 51 | 60 | ||||||
| Payable Days | 141 | 138 | 276 | 301 | ||||||
Zenith Drugs Limited was originally incorporated on November 15, 2000 as a Private Limited Company in the name of ‘Zenith Drugs Private Limited’ under the provisions of the Companies Act, 1956 with the Registrar of Companies, Madhya Pradesh, Gwalior. Subsequently pursuant to a Special Resolution of its Shareholders passed in the Extra-Ordinary General Meeting held on September 05, 2023, the Company was converted from a Private Limited Company to Public Limited Company and consequently, the name of the Company was changed to ‘Zenith Drugs Limited’ and a Fresh Certificate of Incorporation consequent to Conversion was issued on September 13, 2023 by the Registrar of Companies, Gwalior.
The company is a pharmaceutical manufacturing and trading company based out from Indore. It has a manufacturing unit, dedicated to ensuring the highest quality standards when it comes to manufacturing of medicines. It is specialized in manufacturing high quality and affordable Medicines to support its patients in need. The company is also into Generic Medicines and Generic Medicines are cost effective. Since its inception, the company has focused on building a strong foundation and laying the groundwork for its future growth and success. With dedication and strategic planning, it managed to establish a reputable presence in the pharmaceutical industry. The company was incorporated with the objective of the better service deliverance in field of medicine and be better premium pharmaceutical companies in India and abroad for cost effective human medicine. The company always emphasis on core strength and policies that focus on technology and great deliverance. With a passion to set high standards of services, the company has always taken all measures to scale up as and when required only to deliver the better. The company works diligently and has a wide range of products to cater to every need and to reach the client sensitivity and centricity.
The company has Certificate of Good Manufacturing Practices issued by Office of the Controller, Food and Drugs Administration, Madhya Pradesh, Idgah Hills, Bhopal, Madhya Pradesh. The quality standards of the company are based on adherence to Good Manufacturing Practices (GMP) guidelines, regulatory requirements and internal quality control processes. The Company is constantly required to adhere to the same. These measures are implemented to ensure the highest level of quality in its manufacturing operations. Building upon its commitment to excellence, it has completed two expansions within the same facility to accommodate the growing demand for its products. These expansions have allowed the company to scale its operations, increase production capacity, and introduce new formulations. Through these strategic investments and expansions, the company strives to continuously improve its manufacturing infrastructure, enhance product quality, and meet the evolving needs of healthcare professionals and patients.
Business area of the company
The company is mainly engaged in the business of manufacturing and Trading of Medicines.
Products of the company
Liquid oral
Ointment / Cream
Liquid external section
Capsule section
ORS section
History and milestones
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Claim your FREE 15-day access to the most practical investing handbook.
Hurry, limited to the first 10 users today!
FREE Become a savvy and confident
stock investor.
Hurry, limited to the first 10 users today!
Download APP
